Oxford BioMedica concludes novel ocular license deal with Sanofi

17 February 2014

UK-based Oxford BioMedica (LSE: OXB) has concluded the terms of the development and commercialization license agreement with its partner French drug major Sanofi (Euronext: SAN) to develop the novel gene-based medicines for the treatment of ocular diseases, StarGen and UshStat.

Under the terms of the license, Sanofi has been granted broadened global rights across all ocular disease indications for StarGen and UshStatand, in return, Oxford BioMedica will regain the worldwide rights to EncorStat, a treatment for corneal graft rejection.

Under the terms of the collaboration agreement signed in April 2009, Sanofi committed $24 million of development funding that was subsequently prioritized for the advancement of RetinoStat, StarGen and UshStat. In June 2012, Sanofi elected to exercise its options to acquire exclusive worldwide development and commercialization licenses for StarGen and UshStat which triggered an aggregate option exercise payment of $3 million to Oxford BioMedica. Under the new license Oxford BioMedica is eligible for development and commercialization milestone payments and royalties on any future sales of the two products. The parties expect that the management of the ongoing clinical studies will be handed over from the company to Sanofi during the first half of 2014.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology